Genting Xinyao announced that China's State Drug Administration has approved the marketing license application for Starbitol's new drug to treat acute episodes of paroxysmal supraventricular tachycardia in adults, which reverted to sinus heart rhythm. The key phase III RAPID study showed a turnaround rate of 64% within 30 minutes of administration and 31% in the placebo group.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.